ResMed CEO on how wearables, GLP-1s will impact sleep apnea device sales
Oct. 2, 2024
Health Tech Correspondent
NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post-presentation cocktail reception. If the sleep tech magnate could have used more shuteye, he didn’t show it.
Farrell leaned forward enthusiastically to inspect data from a reporter’s Apple smartwatch showing that it hadn’t detected signs of sleep apnea.
advertisement
“Luckily for you, that’s not flashing red,” he joked. “If it was, I’d be selling you a CPAP.”
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$20
for 3 months, then $399/year
$20 for 3 months Get StartedThen $399/year
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe Log In health tech, Medical devices, STAT+ Submit a correction requestReprints
Newsletter
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
